If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit.
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Humulin Summary of Product Characteristics (SmPC)
Humulin® S, Humulin® I, Humulin® M3 100 Units/ml (insulin human): Interaction with other medicinal products and other forms of interaction
Humulin I (isophane insulin), Humulin S (soluble insulin) and Humulin M3 (30% soluble/70% isophane insulin) requirements may increase or decrease in combination with other medicinal products.
A
number of medicinal products are known to interact with glucose
metabolism and therefore the physician should be consulted when using
other medications in addition to human insulin. The physician must
therefore take possible interactions into account and should always
ask his patients about any medicinal products they take.
Insulin
requirements may be increased by substances with hyperglycaemic
activity, such as glucocorticoids, thyroid hormones, growth hormone,
danazol, beta2-
sympatomimetics (such as ritodrine, salbutamol, terbutaline),
thiazides.
Insulin
requirements may be reduced in the presence of substances with
hypoglycaemic activity, such as oral hypoglycaemics (OHA),
salicylates (for example, acetylsalicylic acid), certain
antidepressants (monoamine oxidase inhibitors), certain angiotensin
converting enzyme (ACE) inhibitors (captopril, enalapril),
angiotensin II receptor blockers, non-selective beta-blocking agents
and alcohol.
Somatostatin
analogues (octreotide, lanreotide) may both decrease or increase
insulin dose requirements.
Reference
Humulin
S 100 cartridge Summary of Product Characteristics
Humulin
S 100 vial Summary of Product Characteristics Characteristics
Humulin
I 100 cartridge Summary
of Product Characteristics
Humulin
I 100 SPC KwikPen Summary
of Product Characteristics
Humulin
I 100 SPC vial Summary
of Product Characteristics
Humulin
M3 100 cartridge Summary
of Product Characteristics
Humulin
M3 100 KwikPen Summary
of Product Characteristics
Humulin
M3 100 vial Summary
of Product Characteristics
Date of Last Review:May 30, 2019
Was this answer helpful to you?
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com